SOLUTIONS PRODUCTS INNOVATION INVESTORS ESG
0
Add to list
GB COVID-19 Ag POCT
Cat. No. 4ECO101E
More details>
(3 items)
SOLUTIONS PRODUCTS INNOVATION INVESTORS ESG About GBC Our Brands R&D Media Join us Contact us
English 繁體中文
In Vitro Diagnostics (IVD)
Menu
GB COVID-19 Ag POCT (Professional)
A lateral flow immunoassay that allows for the rapid, qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal swabs specimens directly from individuals who are suspected of COVID-19 by their healthcare provider.
USEFUL RESOURCES
Add to List
>  PRODUCT DESCRIPTION>  FEATURE>  SPECIFICATION>  PERFORMANCE>  ORDERING INFORMATION
PRODUCT DESCRIPTION
The GB COVID-19 Ag POCT is a qualitative membrane-based lateral flow immunoassay technology based on the double antibody-sandwich method. Using this test allows for the rapid detection of nucleocapsid protein from the SARS-CoV-2 swab from patients who are suspected of COVID-19.
FEATURE
  • Easy to perform, no equipment required
  • Fast results
  • High accuracy
SPECIFICATION
Number of tests20
PrincipleLateral Flow Chromatographic Immunoassay
Assay formatQualitative
Time to Results15
Sample typeNasopharyngeal Swab Specimen
StorageRoom Temperature
CertificationTFDA / CE
PERFORMANCE

The clinical performance of the GB COVID-19 Ag POCT was established with individual symptomatic patients who were suspected of COVID-19. The results are as follows:

 PositiveNegative
Positive796
Negative5317
Total84323

Positive percent agreement (PPA): 94.05% (95% CI: 86.65% - 98.04%)
Negative percent agreement (NPA): 98.14% (95% CI: 96.00% - 99.32%)
Accuracy: 97.30% (95% CI: 95.22% - 98.64%)
 

ORDERING INFORMATION
Catalogue No.Product
4LCO009EGB COVID-19 Ag POCT - 20T